0001209191-22-018609.txt : 20220314 0001209191-22-018609.hdr.sgml : 20220314 20220314180146 ACCESSION NUMBER: 0001209191-22-018609 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220310 FILED AS OF DATE: 20220314 DATE AS OF CHANGE: 20220314 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KASINGER JAMES R. CENTRAL INDEX KEY: 0001708172 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 22737992 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS, INC. STREET 2: 610 MAIN STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-10 0 0001674416 CRISPR Therapeutics AG CRSP 0001708172 KASINGER JAMES R. C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 0 1 0 0 General Counsel and Secretary Common Shares 2022-03-10 4 M 0 2834 A 46539 D Common Shares 2022-03-11 4 F 0 1321 62.56 D 45218 D Common Shares 2022-03-11 4 M 0 2250 A 47468 D Common Shares 2022-03-14 4 F 0 1039 61.08 D 46429 D Restricted Stock Units 2022-03-10 4 M 0 2834 D Common Shares 2834 2833 D Restricted Stock Units 2022-03-11 4 M 0 2250 D Common Shares 2250 6750 D Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Includes 163 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on March 10, 2020 with respect to 8,500 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. /s/ Michael Esposito, attorney-in-fact 2022-03-14